SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp (BATL) is trending as investors bet on an oil supply squeeze driven by intensifying geopolitical conflict in the Middle East and the closure of major shipping straits. The community is actively discussing the stock's potential as a short-squeeze candidate, with many expressing bullish sentiment on energy prices and debating the impact of ongoing regional escalations on oil infrastructure.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community debates its long-term utility versus short-term price action, with significant focus on an upcoming token unlock and high expectations for major partnerships in the pipeline. Investors are actively discussing the project's potential integration with institutional rails like XRP and Stellar, fueling a narrative of long-term holding despite current market volatility.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is currently trending as investors debate its long-term AI growth potential against short-term risks from Middle East conflict-driven cloud disruptions and regional volatility. While community sentiment remains split, bulls are actively highlighting aggressive analyst price targets and potential infrastructure buildouts as reasons to accumulate on dips, while bears are focused on bearish technical flow and concerns over macroeconomic headwinds.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF is seeing significant momentum as investors capitalize on surging global military spending and persistent geopolitical tensions, with many in the community viewing it as a strategic long-term play for aerospace and autonomous technology. Traders are actively debating the integration of artificial intelligence and robotics into defense platforms, with many highlighting the ETF's diversified exposure to both domestic and international contractors as a key hedge against macroeconomic uncertainty.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets ($SSB) is trending as the community actively pushes for new exchange listings and chart integrations for associated projects like Maulcoin. Investors are maintaining a focus on long-term growth and utility, while the community continues to rally around the project's ecosystem development and expansion efforts.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently seeing high levels of community engagement driven by the launch of numerous ecosystem projects and ongoing discussions regarding its price action relative to broader market volatility. Investors are actively debating the potential for long-term institutional utility while monitoring key technical levels amidst a period of consolidation.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is experiencing significant institutional accumulation, notably by ARKQ, as investors shift focus toward its expanding global robotaxi footprint across the UAE, Singapore, and beyond. Market participants are increasingly monitoring upcoming Q4 earnings and potential scale-up catalysts, balancing the firm's robust international expansion against ongoing debates regarding the stock's valuation and long-term path to profitability.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is trending due to surging interest in its European gas fields amid heightened geopolitical instability and supply concerns in the energy sector. Investors are closely monitoring the stock's tight float and high cost-to-borrow fees, with community discussions heavily focused on the potential for a short squeeze and the added leverage provided by the company's warrants.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following FDA approval of Vykat XR to treat hyperphagia in Prader-Willi syndrome patients, marking the first therapy of its kind for this rare disease. The community is actively discussing the stock's significant valuation shift, potential for commercial success, and ongoing speculation regarding its status as a high-conviction buyout candidate for larger pharmaceutical players.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

The community is rallying behind $DOG, positioning it as the premier Bitcoin-native memecoin while actively discussing a potential listing on Coinbase. Supporters are focusing on the asset's decentralized structure and fixed supply as key advantages, with many maintaining a bullish outlook for the coming year.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$JNJ J&amp;J announces new long-term 52-week data from Phase 3 Iconic-Advance 1, 2 
 
Johnson &amp; Johnson announced new long-term 52-week data from the Phase 3 Iconic-Advance 1 and 2 and Iconic-Lead studies, which assessed the efficacy and safety of Icotyde in the treatment of patients with moderate-to-severe plaque psoriasis. Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology, AAD, Annual Meeting. Icotyde achieved high levels of complete skin clearance up to Week 52 with no new safety signals:  
 
In the Icotyde treatment arms, rates of completely clear skin increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in Advance-1 and 2, respectively. Patients who switched from placebo to Icotyde at Week 16 achieved similar rates of complete skin clearance by Week 52 as those who were treated with Icotyde for the full 52 weeks. The Icotyde adverse event profile through Week 52 was consistent with that observed through Weeks 16 and 24, and no new safety signal was identified through Week 52. Icotyde overall adverse event and infection rates were lower than deucravacitinib through Week 24.

Enehildo Badillo

StockTwits Web

Johnson & Johnson

 J&J announces new long-term 52-week data from Phase 3 Iconic-Advance 1, 2 
 
Johnson & Johnson announced new long-term 52-week data from the Phase 3 Iconic-Advance 1 and 2 and Iconic-Lead studies, which assessed the efficacy and safety of Icotyde in the treatment of patients with moderate-to-severe plaque psoriasis. Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology, AAD, Annual Meeting. Icotyde achieved high levels of complete skin clearance up to Week 52 with no new safety signals:  
 
In the Icotyde treatment arms, rates of completely clear skin increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in Advance-1 and 2, respectively. Patients who switched from placebo to Icotyde at Week 16 achieved similar rates of complete skin clearance by Week 52 as those who were treated with Icotyde for the full 52 weeks. The Icotyde adverse event profile through Week 52 was consistent with that observed through Weeks 16 and 24, and no new safety signal was identified through Week 52. Icotyde overall adverse event and infection rates were lower than deucravacitinib through Week 24.